Last reviewed · How we verify

NCT02095509

Plasma Anti-FXa Concentration After Continuous Intravenous Infusion and Subcutaneous Dosing of Enoxaparin for Thromboprophylaxis in Critically Ill Patients

Completed Phase 4 Last updated 26 October 2017
What this trial tests

Phase 4 trial testing Enoxaparin in Venous Thromboembolism in 39 participants. Completed in 30 September 2016.

Timeline
1 March 2014
Primary endpoint
30 June 2016
30 September 2016

Quick facts

Lead sponsorTampere University Hospital
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment39
Start date1 March 2014
Primary completion30 June 2016
Estimated completion30 September 2016
Sites2 locations across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Tampere University Hospital

Who can join

Adults 18 to 80, any sex, with Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in critically ill patients by comparing plasma anti-factor Xa activity when enoxaparin is administered either as a continuous intravenous infusion or subcutaneous bolus once daily. To investigate possible ongoing coagulation by coagulation markers during antithrombotic therapy with standard doses of enoxaparin

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Enoxaparin

Trials testing the same drug.

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

Other Tampere University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02095509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing